Compare LINC & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINC | CTMX |
|---|---|---|
| Founded | 1946 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.0M | 596.2M |
| IPO Year | 2005 | 2015 |
| Metric | LINC | CTMX |
|---|---|---|
| Price | $21.77 | $3.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $26.67 | $6.50 |
| AVG Volume (30 Days) | 261.2K | ★ 2.9M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 40.12 | ★ 50.22 |
| EPS | ★ 0.45 | 0.24 |
| Revenue | ★ $494,742,000.00 | $113,631,000.00 |
| Revenue This Year | $17.79 | N/A |
| Revenue Next Year | $9.23 | N/A |
| P/E Ratio | $49.71 | ★ $16.49 |
| Revenue Growth | ★ 16.90 | N/A |
| 52 Week Low | $14.10 | $0.40 |
| 52 Week High | $25.76 | $4.62 |
| Indicator | LINC | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 55.57 | 52.13 |
| Support Level | $20.25 | $3.66 |
| Resistance Level | $22.71 | $4.20 |
| Average True Range (ATR) | 0.96 | 0.25 |
| MACD | 0.24 | -0.03 |
| Stochastic Oscillator | 74.50 | 58.01 |
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include; Campus Operations, and Transitional. The majority of the revenue is generated from the Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.